Skip to content

Advertisement

  • Research
  • Open Access

Prevalence and predictors of metabolic syndrome among people living with human immunodeficiency virus (PLWHIV)

  • Dula Dessalegn Bosho1Email author,
  • Lemessa Dube2,
  • Teshale Ayele Mega1,
  • Dawit Abera Adare3,
  • Mikyas Gashaw Tesfaye3 and
  • Tesfahun Chanie Eshetie1
Diabetology & Metabolic Syndrome201810:10

https://doi.org/10.1186/s13098-018-0312-y

Received: 30 October 2017

Accepted: 12 February 2018

Published: 21 February 2018

Abstract

Background

Use of combination antiretroviral therapy (cART) has led to significant reductions in morbidity and mortality. However, there is a growing concern about metabolic syndromes (MS), among patients receiving cART. Despite this fact, there is limited evidence for the prevalence of the MS among HIV-infected persons receiving cART in developing countries, particularly Ethiopia.

Objective

To determine the prevalence and predictors of MS among people living with HIV/AIDS in Jimma health centre, Jimma Zone south west Ethiopia.

Methods

A cross-sectional study was conducted on people living with HIV/AIDS (PLWHA) in Jimma health centre that fulfilled the inclusion criteria. Data on demographic and anthropometric characteristics were collected using World health organization (WHO) stepwise approach. Fasting blood glucose and lipid profile was measured. The Third Report of National Cholesterol Education Program-adult treatment panel III (NCEP-ATP III)-2001, the International Diabetes Federation (IDF)-2005 and the Joint interim statement-2009 (JIS) criteria were used to define MS. Data were analyzed using statistical software package (SPSS) version 20.0. Logistic regression analysis was done to identify predictors of MS and predictors with p value < 0.05 were used to declare statistical significance.

Results

Of 268 HIV-infected participants included in the analysis, 211 (78.7%) were women. The mean age of the participants was 39.32 ± 10.626 years. Using the NCEP-ATP III criteria, the prevalence of MS was found to be 23.5% (63 patients). While it was 20.5% (55 patients) and 27.6% (74 patients) with IDF and JIS criteria respectively. Enrollment in formal education resulted in 75% increment in the odds of MS (AOR = 0.25, 95% CI [0.072–0.879]). The odds of MS in patients with body mass index > 25 kg/m2 was elevated to 13.4 times (AOR = 13.39, 95% CI [3.943–45.525]) and exposure to D-drugs was attributed to 59% increment in the odds of MS (AOR = 1.59, 95% CI [0.58–4.56]), although the finding lacks statistical significance.

Conclusions

Metabolic syndromes was relatively common to the study population. Hence, promoting health education and monitoring patient’s clinical and laboratory parameters at every visit and taking appropriate measure is ideal.

Keywords

Metabolic syndromeHIV/AIDSEthiopia

Background

Metabolic syndromes (MS) are a cluster of biochemical and anthropometric abnormality that has high predictive ability for the development of atherosclerotic cardiovascular diseases (CVD) [1]. A variety of definitions had been used with different sets of diagnostic criteria, which vary from specific principal elements. But, it generally includes hypertension, obesity, glucose intolerance, hypertriglyceridemia and high density lipoprotein (HDL) dyslipidemia [2]. It is a constellation of cardiovascular risk factors of multifactorial etiology including the use of combination antiretroviral therapy (cART) [3].

Combination antiretroviral therapy (cART) has modified the natural history of human immunodeficiency virus (HIV) infection, leading to a significant reduction in morbidity and mortality. However, long-term toxicity and variety of metabolic abnormalities including dyslipidemia, fat redistribution, high blood pressure, and insulin resistance have frequently been reported, particularly when it contains protease inhibitors [4]. There is also a growing concern that, metabolic complications associated with HIV infection such as, hypertriglyceridemia, low HDL, and weight loss, continue to occur to untreated HIV-infected patients, while lipodystrophy, obesity, hypercholesterolemia, and insulin resistance are increasingly reported among those patients receiving cART [5].

Despite measurable achievements in reducing morbidity and mortality, the cART uses had also given a rise to metabolic and morphologic abnormalities which are risk factors of CVD. Recent finding indicated that, there is a high prevalence of MS among patients receiving ART [6]. However, other data suggested that, the increased prevalence of MS among HIV-infected patients may be more reflective of the burgeoning epidemic of obesity than a predominant effect of ART [7]. Results of the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study showed that, men were more likely than women to have MS and therapy with non-nucleotides reverse transcriptase inhibitors (NNRTIs) may be protective [8].

There is limited evidence for metabolic complications and risk factors of MS in HIV-infected patients in sub-Saharan region, particularly in Ethiopia [9]. Therefore, this study was aimed to investigate the prevalence and predictors of MS among people living with HIV/AIDS in Jimma Health Centre, Jimma Zone South-west Ethiopia.

Method and participants

Study design and study population

This was a cross-sectional study conducted at Jimma health center. The study population was sampled HIV patients attending the clinic for follow-up and on ART. The eligibility criteria for the study participants were; patients aged ≥ 18 years and on follow-up. We exclude patients that refused to sign informed consent or unwilling to participate and those who failed to fast for the next appointment. The health centre serves as an outpatient facility offering HIV care and treatment amongst other services. It is situated in Jimma town, 364 km away from the capital city, Addis Ababa and serves both rural and urban population. It provides services for around 800 HIV positive patients. The study was conducted between April 1 to May 30, 2016.

Sample size calculation and selection of study participants

Sample size of 286 was estimated using a single population proportion formula with the following assumptions; 50% prevalence of metabolic syndrome among general population in Ethiopia, 5% margin of error, 95% confident interval and 10% for non-response. The study participants were selected using simple random sampling technique.

Study variables

Metabolic syndromes among patients receiving cART was considered as an outcome variable and patient related (age, gender, educational level, income, occupation), diseases related (co-morbidities, CD4 count, WHO staging, duration HIV since diagnosed, opportunistic infections), behavioural related (drug use, lifestyle modification) and drug/therapy related factors (concomitant drug therapy, type of cART regimens, duration of cART) were considered as predictor variables.

Data collection

An English version data collection tool adapted from WHO STEP wise approach to chronic disease risk factor surveillance [10, 11] and the patient charts were used to design the data collection tool. Data was collected on socio-demographic and clinical variables both from patients and their charts. The patients’ charts review was followed by collecting all necessary information about the patient. Tools used to collect data on variables such as, anthropometric (weight, height, waist circumference), blood pressure, and heart rate (HR) were standardized prior to be used for actual patient data collection. All measurements were conducted under the standard operating procedure by trained nurses with strict supervision of the principal investigator.

Blood pressure (BP) was measured as the average of the last two of three measurements with the Omron Automatic Inflation Blood Pressure Monitor taken at intervals longer than 2 min after the patient had been sitting for at least 30 min. Anthropometric measurements (waist circumference (WC) was measured with a flexible inelastic tape placed on the midpoint between the lower rib margin and the iliac crest in a perpendicular plane to the long axis of the body. Height was determined without shoes using a portable stadiometer. Weight was measured using a Tanita scale; patients were fully dressed, without heavy clothing or shoes). HR was recorded from the Omron Automatic Inflation Blood Pressure Monitor during blood pressure measurement. Similarly, biochemical measurements such as, fasting blood glucose (FBG), blood lipid, and creatinine were collected following laboratory standard operating procedures by a trained laboratory technologist. Blood sample was collected from each participant on the next morning after fasting for 12 h using vacutainer blood collection system to determine FBG and lipid profile. Five millilitre of blood was drawn from each patient’s cubital vein. Laboratory analysis of sample was done by laboratory technician. Serum samples were analyzed for FBG level and lipid profile [total cholesterol (TC), high density lipoprotein-cholesterol (HDL-c), low density lipoprotein-cholesterol (LDL-c) and triglycerides (TGs)] using ABX Pentra 400 machine. Enzymatic colorimetric assay method was used for the measurement of total cholesterol (CHODPAP method) and triglyceride (GPO-PAP method), while direct homogeneous enzymatic colorimetric assay technique was utilized for the measurement of HDL-c and LDL-c. FBG level was measured by glucose oxidase method (GOD-PAP).

Data analysis and interpretation

Data were cleaned, coded and entered into Epi-Data version 3.1 and exported to the Statistical package for Social Science (SPSS) version 20.0 for analysis. Descriptive statistics using frequency distribution was performed for socio-demographic, epidemiological, clinical, and laboratory values. Association for the predictors and outcome variables were assessed using Chi square test and logistic regression analysis. Multivariate analysis using logistic regression was performed to control effect of confounding variables and to identify the independent predictors of MS. Predictor variables with p value of < 0.05 were used to declare statistically significance.

Outcome definition

The NCEP-ATP III 2001 guidelines define MS as having 3 or more of the following criteria: abdominal obesity (WC ≥ 102 cm for men and ≥ 88 cm for women); TG ≥ 1.7 mmol/L; HDL-c ≤ 1.03 mmol/L in men and ≤ 1.29 mmol/L in women; BP ≥ 130/85 mmHg or on treatment for hypertension; and FBG level of ≥ 6.1 mmol/L or on treatment for diabetes [12]. With IDF 2005-criteria, an individual is considered to have MS if WC ≥ 94 cm for men and ≥ 80 cm for women plus any of two or more of the following: TG ≥ 1.7 mmol/L; HDL–c ≤ 1.03 mmol/L in men and ≤ 1.29 mmol/L in women; BP ≥ 130/85 mmHg or on treatment for hypertension; and FBG level of ≥ 5.6 mmol/L or on treatment for diabetes [2]. Whereas the Joint Interim Statement (JIS) criteria, defines MS as having 3 or more of the following: WC ≥ 90 cm for men and ≥ 80 cm for women; TG ≥ 1.7 mmol/L or on treatment for TGs; HDL-c ≤ 1.0 mmol/L in men and ≤ 1.3 mmol/L in women or on treatment for HDL-c; BP ≥ 130/85 mmHg or on treatment for hypertension; and FBG level of ≥ 5.6 mmol/L or on treatment for elevated glucose will define MS [13].

Results

Of 286 HIV-infected randomly selected patients, 18 of them declined to give informed consent and were excluded from the analysis.

Socio-demographic characteristics of study participants

Among 268 HIV-infected participants included in the analysis, 211 (78.7%) were women. The mean age of participants was 39.32 ± 10.626 years. Majority of them (73.5%) were enrolled in formal education and, 64.2% of these were able to read and write. More than two-third of them (69%) had monthly income of ≤ 500 Ethiopian birr (ETB). About 15 (5.6%) of the participants had history of cigarette smoking and 4 (1.5%) were current smokers. Eighty-nine (33.2%) of them had history of Khat chewing and current chewers were about 17 (6.3%). Those with past history of alcohol consumption were about two-fifth (38.1%) and 38 (14.2%) of them currently drink alcohol 1–4 times per week. Nearly half of them (46.6%) could get fruits 1–2 days per week and majority of them (52.6%) were physically inactive (Table 1).
Table 1

Socio-demographic characteristic of people living with HIV/AIDS at follow up in Jimma health centre ART clinic, April 01 to May 30, 2016

Variables

Frequency, N = 268 (%)

Sex

 Male

57 (21.3)

 Female

211 (78.7)

Age (years)

 18–30

60 (22.4)

 31–40

109 (40.7)

 41–50

61 (22.8)

 > 50

38 (14.2)

Able to write and read

 No

96 (35.8)

 Yes

172 (64.2)

Enrolled in formal education

 Yes

197 (73.5)

 No

71 (26.5)

Monthly income in ETB

 ≤ 500

185 (69.0)

 501–1500

67 (25.0)

 1501–2500

7 (2.6)

 ≥ 2501

9 (3.4)

Cigarette smoking history

 No

253 (94.4)

 Yes

15 (5.6)

Current smoker

 No

264 (98.5)

 Yes

4 (1.5)

Khat chewing history

 No

179 (66.8)

 Yes

89 (33.2)

Current Khat chewer

 No

72 (26.9)

 Yes

17 (6.3)

Current alcohol consumption

 No

166 (61.9)

 Yes

102 (38.1)

Frequency of alcohol drink in past 12 months

 4 drinks per week

38 (14.2)

 2 drinks per week

38 (14.2)

 Less than one a month

26 (9.7)

Fruit intake

 None

78 (29.1)

 1–2 days/week

125 (46.6)

 3–4 days/week

41 (15.3)

 5–7 days/week

24 (9.0)

Physical activity

 Inactive

141 (52.6)

 Active

127 (47.4)

ETB Ethiopian birr

Clinical and drug related characteristics

One hundred and seventeen (43.7%) patients had reported that their BP was measured. About 36.6% of them had their BP measured in the past 12 months. Around 17 (6.3%) of them reported that they had been told by health care professional they had hypertension. Of these, 5 (1.9%) were receiving anti-hypertensive medication in the past 2 weeks. About 3.4% of patients were asthmatic and 3 (1.1%) had chronic kidney diseases.

Nearly half of the patients (48%) were WHO stage 2 and majority of them (53.7%) had lived 6 years and above with HIV/AIDS. Most of them (83.2%) had CD4 count less than 350 cell/mm3 at baseline and 226 (84.3%) had opportunistic infections (OIs) prior to HIV diagnosis. More than half (52.6%) of them were receiving TDF + 3TC + EVF at base line and about 60.8% of them were taking ART for less than 5 years. Moreover, 52.6% of the participants were receiving cotrimoxazole for prevention of OIs together with cART (Table 2).
Table 2

Clinical and drug related characteristics of people living with HIV/AIDS at follow up in Jimma health centre ART clinic, April 01 to May 30, 2016

Variables

Frequency N = 268 (%)

History of BP measured by health workers

 No

151 (56.3)

 Yes

117 (43.7)

Period of blood pressure measured

 The past 12 months

98 (36.6)

 Within past 1–5 years

16 (6.0)

 More than past 5 years

3 (1.1)

Previous history of hypertension

 No

251 (93.7)

 Yes

17 (6.3)

Taking antihypertensive agent past 2 weeks

 No

16 (4.5)

 Yes

5 (1.9)

Previous history of asthma

 No

259 (96.6)

 Yes

9 (3.4)

Previous history of chronic kidney diseases

 No

265 (98.9)

 Yes

3 (1.1)

Duration of HIV diagnosis

 ≤ 5 years

122 (45.5)

 ≥ 6 years

146 (54.5)

CD4 (cell/mm3)

 < 350

223 (83.2)

 351–550

38 (14.2)

 ≥ 551

7 (2.6)

WHO stage

 I

48 (17.9)

 II

129 (48.1)

 III

83 (31)

 IV

8 (3)

OIs prior to HIV diagnosis

 Yes

226 (84.3)

 No

42 (15.7)

Types of cART regimes at baselines

 D-drugsa

92 (34.3)

 Othersb

176 (65.7)

Duration of cART (years)

 ≤ 5

163 (60.8)

 ≥ 6

99 (36.9)

 Othersc

6 (2.2)

Concomitants drug use

 Cotrimoxazole

141 (52.6)

 INH

30 (11.2)

 Multivitamins

6 (2.2)

 Othersd

13 (4.9)

BP blood pressure, HIV human immunodeficiency virus, CD4 cluster differentiation 4, OIs opportunistic infections, URTIs upper respiratory tract infections, cART combination antiretroviral therapy, d4T stavudine, 3TC lamivudine, AZT zidovudine, TDF tenofovir, NVP nevirapine, EVF efavirenz, INH isoniazid

ad4T + 3TC + NVP; d4T + 3TC + EVF

bAZT + 3TC + NVP; AZT + 3TC + EVF; TDF + 3TC + EVF; TDF + 3TC + NVP

cNaïve patients

dEnalapril, hydrochlorothiazide, atenolol, prednisolone, salbutamol puff

Physical, biochemical measurements and prevalence of MS

Physical and biochemical measurements indicated that, nearly two-fifth (38.4%) of the patients had hypertension and almost more than two-third of them (68.5%) had normal body weight. About 18.7% of the patients’ WC was in line with the definition of MS. HDL-c was the most prevalent components of MS 132 (49.3%) followed by BP 103 (38.4%). Therefore, according to NCEP-ATP III, the prevalence of MS was 63 (23.5%), and it was 55 (20.5%) according to IDF. Similarly, the prevalence of MS was 74 (27.6%) according to JIS (Table 3).
Table 3

Physical and biochemical measurements among people living with HIV/AIDS at follow up in Jimma health centre ART clinic, April 01 to May 30, 2016

Variables

Frequency, N = 268 (%)

Components of MS

Blood pressure

 SBP ≥ 130 mmHg and DBP ≥ 85 mmHg

103 (38.4%)

103 (38.4%)

BMI (kg/m2)

 < 18.5

50 (18.7)

 

 18.5–24.9

184 (68.7)

 

 ≥ 25

34 (12.7)

 

WC

 Male ≥ 102 cm

2 (0.7)

 

 Female ≥ 88 cm

48 (17.9)

50 (18.7)

FBG ≥ 100 mg/dl

46 (17.2)

46 (17.2)

TC ≥ 200 mg/dl

67 (25.0)

 

HDL-c ≤ 40 mg/dl male and ≤ 50 mg/dl female

132 (49.3)

132 (49.3)

TGs ≥ 150 mg/dl

80 (29.9)

80 (29.9)

LDL-c ≥ 100 mg/dl

101 (37.7)

 

SBP systolic blood pressure, DBP diastolic blood pressure, BMI body mass index, WC waist circumference, FBG fasting blood glucose, TC total cholesterol, HDL high density lipoprotein-cholesterol, TGs triglycerides, LDL low density lipoprotein-cholesterol

Predictors of metabolic syndrome

The result of binary logistic regression analysis of the independent predictors showed that age group 41–50 years and those not enrolled in formal education were significantly associated with MS (COR = 3.171, 95% CI 1.268–7.928, and COR = 0.384, 95% CI 0.179–0.827) respectively. In addition, monthly income level above 2501 ETB (COR = 4.141, 95% CI 1.007–17.02) was also associated with MS. Moreover, physical activity (COR = 0.558, 95% CI 0.312–0.999), duration of HIV diagnosis less than 5 years (COR = 0.286, 95% CI 0.151–0.543), body mass index ≥ 25 kg/m2 (COR = 10.47, 95% CI 3.513–31.24), duration of ART regimens for more than 6 years (COR = 3.011, 95% CI 1.676–5.410), and type of cART regimens (COR = 2.927, 95% CI 1.635–5.238) were significantly associated with MS.

Multivariable logistic regression analysis was done for all explanatory variables with p < 0.25 in bivariate logistic regression analysis. Accordingly, those not enrolled in formal education and body mass index above 25 kg/m2 were independent predictors of MS. Therefore, those who were not enrolled in formal education were less likely to have MS (AOR = 0.252, 95% CI 0.072–0.879) and overweight patients were 13.4 times more likely to have MS (AOR = 13.398, 95% CI 3.943–45.525) (Table 4).
Table 4

Predictors of MS among PLWHIV at follow up in Jimma health centre ART clinic, April 01 to May 30, 2016

Variables

MS according to (NCEP-ATP III)

Bivariate analysis

Multivariate analysis

p value

COR (95% CI)

p value

AOR (95% CI)

Yes

No

Sex

 Male

12

45

0.623

0.837 (0.411–1.703)

  

 Female

51

160

1

1

  

Age in years

 18–30

8

52

1

1

1

1

 31–40

24

85

0.172

1.835 (0.768–4.387)

0.538

1.358 (0.513–3.594)

 41–50

20

41

0.014

3.171 (1.268–7.928)

0.175

2.058 (0.725–5.847)

 ≥ 51

11

27

0.062

2.648 (0.953–7.362)

0.344

1.782 (0.539–5.894)

Able to write or read

 No

17

79

0.097

0.589 (0.316–1.099)

0.979

1.014 (0.355–2.899)

 Yes

46

126

1

1

1

1

Formal education

 Yes

54

143

1

1

1

1

 No

9

62

0.014

0.384 (0.179–0.827)

0.031

0.252 (0.072–0.879)

Smoking history

 No

61

192

1

1

  

 Yes

2

13

0.349

0.484 (0.106–2.206)

  

Past Khat chewer

 No

46

133

1

1

1

1

 Yes

17

72

0.232

0.683 (0.365–1.277)

0.583

0.813 (0.388–1.704)

Current Khat chewer

 No

14

58

1

1

  

 Yes

3

14

0.865

0.888 (0.224–3.517)

  

Alcohol consumption

 No

39

127

1

1

  

 Yes

24

78

0.995

1.002 (0.560–1.792)

  

Frequency of alcohol

 1–4 days/weeks

11

27

1

1

  

 1–3 days/weeks

8

30

0.428

0.655 (0.229–1.868)

  

 < Once a month

5

21

0.381

0.584 (0.176–1.943)

  

Physical activity

 Inactive

40

101

1

1

1

1

 Active

23

104

0.050

0.558 (0.312–0.999)

0.325

0.702 (0.347–1.420)

Fruit intake

 None

23

55

1

1

1

1

 1–2 days/week

27

98

0.206

0.659 (0.345–1.258)

0.103

0.513 (0.230–1.145)

 3–4 days/week

9

32

0.380

0.673 (0.277–1.630)

0.621

0.767 (0.269–2.190)

 5–7 days/week

4

20

0.220

0.478 (0.147–1.554)

0.334

0.513 (0.132–1.986)

Comorbid disease

 No

53

187

1

1

1

1

 Yes

10

18

0.112

1.960 (0.854–4.500)

0.543

1.383 (0.486–3.930)

Duration of HIV

 ≤ 5 years

15

107

< 0.001

0.286 (0.151–0.543)

0.136

0.482 (0.185–1.259)

 > 5 years

48

98

1

1

1

1

CD4 (cell/mm3)

 < 350

53

170

1

1

  

 351–550

9

29

0.991

0.995 (0.443–2.235)

  

 ≥ 551

1

6

0.566

0.535 (0.063–4.541)

  

WHO stages

 Stage I

12

35

1

1

  

 Stage II

28

101

0.592

0.809 (0.371–1.760)

  

 Stage III

21

63

0.946

0.972 (0.428–2.209)

  

 Stage IV

2

6

0.975

0.972 (0.172–5.481)

  

Duration of cART

 ≤ 5 years

26

137

1

1

1

1

 > 5 years

36

63

< 0.001

3.011 (1.676–5.410)

0.372

1.563 (0.586–4.173)

 Othersa

1

5

0.963

1.054 (0.118–9.394)

0.735

1.499 (0.143–15.666)

Types of cART

 D-drugsb

33

56

< 0.001

2.927 (1.635–5.238)

0.366

1.591 (0.581–4.360)

 Othersc

30

149

1

1

1

1

BMI (kg/m2)

 < 18.5

6

44

1

1

1

1

 18.5–24.9

37

147

0.195

1.846 (0.731–4.660)

0.129

2.191 (0.795–6.036)

 ≥ 25

20

14

< 0.001

10.47 (3.513–31.24)

< 0.001

13.398 (3.943–45.525)

COR crude odd ratio, AOR adjusted odd ratio, HIV human immunodeficiency virus, CD4 cluster determinant 4, WHO world health organization, cART combination antiretroviral therapy, BMI body mass index, d4T stavudine, 3TC lamivudine, AZT zidovudine, TDF tenofovir, NVP nevirapine, EVF efavirenz

aNaïve patients

bd4T + 3TC + NVP/or EVF

cAZT/or TDF + 3TC + NVP/or EVF and naïve patients

Discussion

In this study, the prevalence of MS was 23.5, 20.5 and 27.6% by NCEP-ATP III, IDF and JIS respectively. The JIS result of MS in our finding was higher than the others two. This finding was consistent with the study conducted in Malaysia (26.5, 37.4 and 43.4%) [13] and South Africa (24.1, 25.5, and 28.2%) respectively [14]. The prevalence of MS according to JIS in our study was in closer to the finding from South Africa i.e. 28.2% [14]. NCEP-ATP III did not use any single risk factor (e.g. abdominal obesity) as a requirement for MS diagnosis. The IDF clinical definition thus uses the presence of abdominal obesity necessary for diagnosis. If this is the case, 2 additional factors originally listed in the NCEP-ATP III definition are sufficient to diagnose MS [15]. This makes variation in NCEP-ATP III and IDF definition of MS.

Based on NCEP-ATP III criteria, our finding was higher than results obtained from Darlinghurst and Southern Brazil, in which the prevalence of MS was 18, 17.2% respectively [16, 17]. Our finding was also higher than the study from Hawassa University Referral Hospital and Jimma University specialized hospital, where the prevalence of MS was 18.1 and 21.1% respectively [18, 19]. This variation might be due to the fact that, there were higher numbers of participants with low HDL and high blood pressure in our study. The other possible explanation might be our study was done in primary health care setting unlike that of Hawassa and JUSH, which are referral settings with high level of care and professional profile. On the other hand, our finding was in line with the study from Thailand in which 22.2% of participants had MS [5]. Our finding was lower than the results obtained from Danish, where 27% of the participants were found to be victims of MS [20]. This difference might be due to the variation in different components of MS (WC, high FBG and TGs) which was lower in our study and the small sample size utilized in our study.

The prevalence of MS using IDF criteria in our study was higher than the study conducted in Darlinghurst (i.e. 14%) [16]. This variation might be due to the higher proportions of women (78.7%) in our study and WC can be considered as basic parameters for MS diagnosis in IDF criteria. However, the Darlinghurst study considered only men patients. In contrary, the prevalence of MS using IDF criteria in our finding was lower than the finding from Hawassa university referral hospital [18]. This discrepancy might be due to use of abdominal obesity as basic requirement for diagnosing MS by IDF criteria. There were lower proportions of patients that had high abdominal obesity in our finding.

This study revealed that, being enrolled in formal education was independent predictor of MS. Similar finding was also reported from Nairobi [21]. This could be justified by the higher proportions (72.8%) of patients’ enrolled in formal education were receiving D-drugs, which were well known risk of MS as reported by other study [18]. The prevalence of MS increased with age [22], but age groups were not predictors of MS in our finding, unlike reports from Hawassa University referral hospital and Nairobi [18, 21]. This difference might be due to variation in age group (i.e. more than three-fifth of them had < 40 years old in our study).

The participant’s characteristics like smoking habit, alcohol consumption, physical activity and Khat chewing were not identified as independent predictors’ of MS. This was consistent with finding from Hawassa University referral hospital [18]. This study also showed that, body mass index of ≥ 25 kg/m2 was independent predictor of MS. This was in line with the study done in Hawassa University referral hospital [18].

The most frequently observed features of abnormalities were lower HDL (49.3%), raised BP (38.4%) and raised LDL (37.7%), while TGs (29.9%), TC (18.7%) and FBG (17.2%) were less common.

The development of cART-associated MS is complex and a number of factors including direct effects of ART on lipid metabolism, endothelial and adipocyte cell function, and mitochondria [23] could be implicated. Cumulative evidence has pointed out the relationship between different metabolic disorders and cART use, including insulin resistance, hyperlipidemia, and lipodystrophy, even though it remains controversial whether this effect can be directly ascribed to cART [24]. Although capturing the impact on duration of specific drug on the development of MS could be impossible, it seemed cART duration could have an impact. This might be hypothesized by our finding that, patients who received cART more than 5 years has 15.6% higher odds of having MS than those below 5 year, although our finding lacked statistical significance. Similar results were reported by study done in Hawassa University referral hospital [18]. In contrast, study done in Jimma University specialized hospital had witnessed the impact of long term exposure (> 12 months) of cART on MS [19]. This difference might be due to variation in years of cART duration categories in the statistical analysis. Likewise, the odds of having MS was increased by 15.9% among patients’ treated with D-drugs, however, the difference was statistically insignificant. The study conducted in Hawassa University referral hospital, showed that receiving D4T − 3TC − EFV regimen was significantly associated with higher odds of MS [18].

As one of its strength, this study tried to high light the prevalence and some of the risk factors of MS in low income settings, which was not fully understood in HIV-infected patients. However, the anticipation of early diagnosis for its components should be part of the good clinical practices. Consequently, doing so might contribute to slow or even reduce its impact on the development of CVD. However, our study had some limitation. Being a single center study and focused on primary care setting could affect the generalizability.

Conclusions

Metabolic syndromes were relatively common to HIV/AIDS patients in a primary care setting. In our finding one in four of the study participants had MS. Low level of HDL-c and high BP as a component of the five MS criteria were more prevalent in our study population. The study revealed that enrollment in formal education and overweight were independent predictors of MS.

Declarations

Authors’ contributions

DDB conceived and led the study acquisition of data, interpretation of data, performed the statistical analysis and revised manuscript for intellectual content, edited the manuscript; LD conceived and led the study acquisition of data, performed statistical analysis, revised manuscript for intellectual content; TAM assisted with interpretation of data, performed statistical analysis, drafted the manuscript, edited the manuscript; MGT, DAA interpretation of data, and revised manuscript for intellectual content; TCE conceived and led the study acquisition of data, interpretation of data, performed the statistical analysis. All authors read and approved the final manuscript.

Acknowledgements

We would like to thank the participants, and the data collectors (nurses and laboratory technologists of Jimma health center) for their immense contribution of this work. Our heartfelt gratitude should also go to Jimma University for facilitating this study.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

The original data of this study could be available for the third body only up on author’s request.

Consent for publication

No applicable.

Ethics approval and consent to participate

Ethical approval was obtained from the Institutional Review Board of the College of Health Science, Jimma University, Jimma, Ethiopia. Informed consent was obtained from all participants to conduct the study.

Funding

Not applicable.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Pharmacy, Faculty of Health Sciences, Institute of Health, Jimma University, Jimma, Ethiopia
(2)
Department of Epidemiology, Public Health Faculty, Institute of Health, Jimma University, Jimma, Ethiopia
(3)
Department of Medical Laboratory, Jimma University Medical Centre, Institute of Health, Jimma University, Jimma, Ethiopia

References

  1. Iloh GUP, Okafor GOC, NkwaAmadi A. Epidemiology of metabolic syndrome among adult Nigerians in a rural hospital in Eastern Nigeria. Sci J Public Health. 2014;2:135–43.Google Scholar
  2. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med. 2006;23:469–80.View ArticlePubMedGoogle Scholar
  3. Miranda PJ, Defronzo RA, Califf RM, Guyton JR. Metabolic syndrome: definition, pathophysiology and mechanisms. Am Heart J. 2005;149:33–45.View ArticlePubMedGoogle Scholar
  4. Jerico C, Knobel H, Montero M, Ordonez-Llanos J, Guelar A. Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care. 2005;28:144–9.View ArticleGoogle Scholar
  5. Jantarapakde J, Phanuphak N, Chaturawit C, Pengnonyang S, Mathajittiphan P, Takamtha P, et al. Prevalence of metabolic syndrome among antiretroviral-naive and antiretroviral-experienced HIV-1 infected Thai adults. AIDS Patient Care STDs. 2014;28:7.View ArticleGoogle Scholar
  6. Mondy K, OvertonET Grubb J, Tong S, Seyfried W, Powderly W, et al. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis. 2007;44:726–34.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Ford ES, Giles WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2004;287:356–9.View ArticleGoogle Scholar
  8. Sobieszczyk ME, Hoover DR, Anastos K, Mulligan K, Tan T, Shi Q, et al. Prevalence and predictors of metabolic syndrome among HIV-infected and HIV uninfected women in the women’s interagency HIV study. J Acquir Immune Defic Syndr. 2008;48:272–80.View ArticlePubMedGoogle Scholar
  9. Dimodi HT, EtameLS Nguimkeng BS, Mbappe FE, Ndoe NE, Tchinda JN, et al. Prevalence of metabolic syndrome in HIV-infected Cameroonian patients. World J AIDS. 2014;4:85–92.View ArticleGoogle Scholar
  10. World Health Organization. WHO STEPS instrument (core and expanded). The WHO STEPwise approach to noncommunicable disease risk factor surveillance. Geneva: World Health Organization; 2010.Google Scholar
  11. World Health Organization. WHO STEPS instrument. Geneva: World Health Organization; 2012.Google Scholar
  12. Expert Panel on Detection E. Executive summary of the third report of the national cholesterol educational program (NCEP) expert panel on detection, evaluation and treatment of high cholesterol in adults (Adult treatment III). JAMA. 2005;285:2486–97.Google Scholar
  13. Ramli AS, Daher AM, Nor-Ashikin MNK, Mat-Nasir N, Ng KK, Miskan M, et al. JIS definition identified more Malaysian adults with metabolic syndrome compared to the NCEP-ATP III and IDF criteria. Biomed Res Int. 2013;2013:1–10.View ArticleGoogle Scholar
  14. Nguyen KA, Peer N, Villiers A, Mukasa B, Matsha TE, Mills EJ, et al. Metabolic syndrome in people living with human immunodeficiency virus: an assessment of the prevalence and the agreement between diagnostic criteria. Int J Endocrinol. 2017;2017:1–8.View ArticleGoogle Scholar
  15. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung and Blood Institute scientific statement. Circulation. 2005;112:2735–52.View ArticlePubMedGoogle Scholar
  16. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III Criteria. Diabetes Care. 2007;30:113–9.View ArticlePubMedGoogle Scholar
  17. Alencastro PR, Fuchs SC, Wolff FH, Ikeda ML, Brandão AB, Barcellos NT. Independent predictors of metabolic syndrome in HIV-infected patients. AIDS Patient Care STDs. 2011;25:11.View ArticleGoogle Scholar
  18. Tesfaye DY, Kinde S, Medhin G, Megerssa YC, Tadewos A, Tadesse E, et al. Burden of metabolic syndrome among HIV-infected patients in Southern Ethiopia. Diabetes Metab Syndr Clin Res Rev. 2014;8:102–7.View ArticleGoogle Scholar
  19. Berhane T, Yami A, Alemseged F, Yemane T, Hamza L, Kassim M, et al. Prevalence of lipodystrophy and metabolic syndrome among HIV positive individuals on highly active anti-retroviral treatment in Jimma, South West Ethiopia. Pan Afr Med J. 2012;13:43.PubMedPubMed CentralGoogle Scholar
  20. Hansen BR, Petersen J, Haugaard SB, Madsbad S, Obel N, Suzuki Y, et al. The prevalence of metabolic syndrome in Danish patients with HIV infection: the effect of antiretroviral therapy. HIV Med. 2009;10:378–87.View ArticlePubMedGoogle Scholar
  21. Kaduka LU, Kombe Y, Kenya E, Kuria E, Bore JK, Bukania ZN, et al. Prevalence of metabolic syndrome among an urban population in Kenya. Diabetes Care. 2012;35:887–93.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Worm SW, Friis-Møller N, Bruyand M, Monforte ADA, Rickenbach M, Reiss P, et al. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS. 2010;24:427–35.View ArticlePubMedGoogle Scholar
  23. Barbaro G. Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection: HAART-associated metabolic syndrome; molecular mechanisms. Curr HIV Res. 2006;4:79–85.View ArticlePubMedGoogle Scholar
  24. Wand H, Calmy A, Carey DL, Samaras K, Carr A, Law MG, et al. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS Patient Care STDs. 2007;21:2445–53.Google Scholar

Copyright

© The Author(s) 2018

Advertisement